| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 3,851 | 4,052 | ||
| General and administrative | 1,767 | 2,569 | ||
| Total operating expenses | 5,618 | 6,621 | ||
| Loss from operations | -5,618 | -6,621 | ||
| Change in fair value of financial instruments | -2,000 | - | ||
| Interest expense | 326 | - | ||
| Interest income | 140 | - | ||
| Other income | 0 | - | ||
| Total other income (expense) | -2,186 | - | ||
| Net loss | -7,804 | -6,000 | ||
| Earnings per share, basic, total | -0.52 | -0.4 | ||
| Earnings per share, diluted, total | -0.52 | -0.4 | ||
| Weighted-average number of shares outstanding used in computing net loss per share - basic | 15,076,456 | 14,995,404 | ||
| Weighted-average number of shares outstanding used in computing net loss per share - diluted | 15,076,456 | 14,995,404 | ||
CalciMedica, Inc. (CALC)
CalciMedica, Inc. (CALC)